Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company’s STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, … [Read more…]

Merz Aesthetics® Announces EU Approval of Two New Indications for Their Hyaluronic Acid Filler BELOTERO® Balance

FRANKFURT, Germany–(BUSINESS WIRE)–Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, is pleased to announce that BELOTERO® Balance has received EU approval for two additional indications: the treatment of infraorbital hollow (including the tear trough) and horizontal forehead lines1*. “With these new approvals, BELOTERO® Balance further strengthens its position as a versatile hyaluronic acid dermal … [Read more…]

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 Results demonstrate the potential for Camzyos to be the first targeted pharmacological therapy for the treatment of oHCM in adolescents Safety profile of Camzyos in adolescents was similar to established profile in … [Read more…]

Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC

Patients treated with tonlamarsen experienced statistically significant reductions in plasma angiotensinogen levels and clinically meaningful changes in systolic blood pressure Results support initiation of Phase 2b clinical trial of tonlamarsen in patients with acute severe hypertension SOUTH SAN FRANCISCO, Calif., & PRINCETON, N.J.–(BUSINESS WIRE)–#ACC26—Kardigan™, a clinical-stage precision therapeutics company developing medicines that target the root … [Read more…]

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with … [Read more…]

Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device (SaMD) that detects early signs of PH, a serious and progressive condition affecting the lungs and right side of the heart. The algorithm, which previously received FDA Breakthrough … [Read more…]

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #Cobenfy—Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when switching adult outpatients with schizophrenia from … [Read more…]

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website. The third‑party article incorrectly claimed that Panna … [Read more…]

Banner|Aetna Brings Community Together for 2026 Phoenix Heart Walk

Arizona health plan continues its longstanding support of cardiovascular research and prevention at the Phoenix Heart Walk PHOENIX–(BUSINESS WIRE)–#Aetna—Banner|Aetna, an Arizona-based health plan offering integrated coverage and care through a partnership between Banner Health and Aetna, a CVS Health company, is participating in the 2026 Phoenix Heart Walk on March 28. Organized by the American … [Read more…]

“Cold-blooded decision on hospital funding,” says CUPE in response to Ford government’s 2026 budget

TORONTO–(BUSINESS WIRE)–The real dollar hospital funding cut announced in the 2026 provincial budget will intensify the crisis in Ontario’s hospitals, which are already funded at the lowest rate in the country, says the Canadian Union of Public Employees. “The government increased hospital funding by four per cent – a real cut of two per cent … [Read more…]